News
DuPont Nutrition & Biosciences Enters into Collaboration with Microbiome Specialist MRM Health
DuPont Nutrition & Biosciences announced a collaboration with the MRM Health NV, a biopharmaceutical company, focused on the discovery and development of innovative therapeutics based on the human microbiome. MRM Health also confirmed the successful completion of its first...
News
Key Themes and Technologies Highlighted at Pharmapack Europe 2020
Improving adherence to medication via smarter, patient-centric pharmaceutical packaging and extracting further value from existing medicines and delivery devices are two of the latest key strategies aimed at reducing waste and protecting the bottom line, according to experts at...
News
Almac Group launches enhanced Label Approval Solution (LAS)
Almac Clinical Services, a member of the global contract pharmaceutical development and manufacturing organisation, the Almac Group, has announced the launch of its enhanced Label Approval Solution (LAS) – a fully compliant and validated system providing sponsors with an...
News
Bayer, Nuvisan to create drug discovery research unit in Berlin
NUVISAN has agreed with Bayer to integratelarge partsof Bayer’s Berlin-based small molecule research unit and complementshereby its services in the field of preclinical research. NUVISAN is an international service provider for clinical studies, laboratory services and contract manufacturing (CRO...
News
PCI Pharma Services Announces the Acquisition of Bellwyck Pharma Services
PCI Pharma Services (PCI), a leading pharmaceutical and biopharmaceutical global supply chain solutions provider, announced the acquisition of Bellwyck Pharma Services (Bellwyck), headquartered in Toronto, Canada. With 25 years of experience, Bellwyck is a leader in primary and secondary...
Clinical Trials
Light Chain Bioscience Successfully Completes Factor VIII Mimetic Bispecific Antibody Discovery
Light Chain Bioscience has achieved a milestone and received a payment under its research and collaboration agreement with Takeda Pharmaceutical. The milestone was achieved upon the successful completion of the discovery phase and designation by Takeda of undisclosed bispecific...
News
WuXi Biologics Provides Back-to-work Operation Update Related to the Coronavirus Outbreak
WuXi Biologics is closely monitoring the coronavirus outbreak. Our management team is working vigilantly to execute our Business Continuity Plan to mitigate any potential risk. All three operating sites in China, namely Wuxi, Shanghai and Suzhou, will resume operations...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from any location or device.
















